Last reviewed · How we verify
Anthralin (dithranol)
At a glance
| Generic name | dithranol |
|---|---|
| Drug class | dithranol |
| Target | Arachidonate 12-lipoxygenase, 12R-type, NAD-dependent protein deacylase sirtuin-5, mitochondrial, Serine protease hepsin |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
- Transient primary irritation
- Staining of hair
- Staining of skin
- Temporary discoloration of hair
- Temporary discoloration of skin
- Staining of fabrics
Serious adverse events
- Contact allergic reactions
Key clinical trials
- PGE2/IL-22 Pathway in Various Forms of Eczema
- Evaluation of Vitamin D Levels in Psoriasis Patients
- Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis (PHASE4)
- Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis (PHASE4)
- Study on the Therapeutic Mechanisms of Dithranol Treatment in Patients With Chronic Plaque Psoriasis
- Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anthralin CI brief — competitive landscape report
- Anthralin updates RSS · CI watch RSS
- portfolio CI